AstraZeneca: Aspirin May Be To Blame For Poor Results In Some Brilinta Trial Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Uncertainty over aspirin usage among a North American subgroup of trial patients continues to raise speculation about an FDA review.